Cancers, Vol. 12, Pages 284: Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

Conclusions: Our in silico and experimental analyses suggest that non-small cell lung carcinoma will likely respond to a new generation of anti-CTLA-4 monoclonal antibodies. Our approach provides an objective ranking of the sensitivity of human cancers to anti-CTLA-4 antibodies. The comprehensive ranking of major cancer types provides a roadmap for clinical development of the next generation of anti-CTLA-4 antibodies.

Source: Cancers - January 23, 2020 Category: Cancer & Oncology Authors: Zhang Xiong Rolfo Du Zhang Yang Russo Devenport Zhou Liu Zheng Tags: Article Source Type: research